JP2010513561A - Ｉａｐのイミダゾピリジンインヒビター - Google Patents

Ｉａｐのイミダゾピリジンインヒビター Download PDF

Info

Publication number
JP2010513561A
JP2010513561A JP2009543099A JP2009543099A JP2010513561A JP 2010513561 A JP2010513561 A JP 2010513561A JP 2009543099 A JP2009543099 A JP 2009543099A JP 2009543099 A JP2009543099 A JP 2009543099A JP 2010513561 A JP2010513561 A JP 2010513561A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycle
carbocycle
optionally substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009543099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513561A5 (enExample
Inventor
マイケル エフ．ティ． コーラー，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2010513561A publication Critical patent/JP2010513561A/ja
Publication of JP2010513561A5 publication Critical patent/JP2010513561A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009543099A 2006-12-19 2007-12-14 Ｉａｐのイミダゾピリジンインヒビター Ceased JP2010513561A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87082106P 2006-12-19 2006-12-19
PCT/US2007/087532 WO2008079735A1 (en) 2006-12-19 2007-12-14 Imidazopyridine inhibitors of iap

Publications (2)

Publication Number Publication Date
JP2010513561A true JP2010513561A (ja) 2010-04-30
JP2010513561A5 JP2010513561A5 (enExample) 2011-02-03

Family

ID=39361343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543099A Ceased JP2010513561A (ja) 2006-12-19 2007-12-14 Ｉａｐのイミダゾピリジンインヒビター

Country Status (12)

Country Link
US (2) US8063218B2 (enExample)
EP (1) EP2125809A1 (enExample)
JP (1) JP2010513561A (enExample)
KR (1) KR20090094461A (enExample)
CN (1) CN101605786A (enExample)
AU (1) AU2007337104A1 (enExample)
BR (1) BRPI0719481A2 (enExample)
CA (1) CA2671607A1 (enExample)
IL (1) IL198927A0 (enExample)
NZ (1) NZ577150A (enExample)
RU (1) RU2466131C2 (enExample)
WO (1) WO2008079735A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502397A (ja) * 2017-11-13 2021-01-28 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JP2022531794A (ja) * 2019-05-10 2022-07-11 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773766B1 (en) * 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
AR063943A1 (es) * 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CN101687787A (zh) * 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
NZ590550A (en) * 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
PL2611797T3 (pl) * 2010-08-31 2017-05-31 Hanmi Science Co., Ltd. Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
AU2020233068B2 (en) * 2019-03-07 2025-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of IAP inhibitor and immune checkpoint inhibitor
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
JP2006501181A (ja) * 2002-07-02 2006-01-12 ノバルティス アクチエンゲゼルシャフト Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
WO2006069063A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
EP1315811A2 (en) 2000-08-24 2003-06-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
US20030157522A1 (en) 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
ES2318167T3 (es) 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
AU2003216203A1 (en) 2003-02-07 2004-09-06 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20040171554A1 (en) 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
SE0301904D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US7067274B2 (en) 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
CA2582734C (en) 2004-03-01 2011-05-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
MXPA06014969A (es) 2004-07-02 2007-02-08 Genentech Inc Inhibidores de iap.
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CN1808446A (zh) * 2005-01-22 2006-07-26 鸿富锦精密工业（深圳）有限公司 高速电路中耦合传输线等效模型的撷取方法
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501181A (ja) * 2002-07-02 2006-01-12 ノバルティス アクチエンゲゼルシャフト Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2006069063A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012032836; Ｅｕｒ．　Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．３５, 2000, ｐ．２５７-６６ *
JPN6012032836; Ｊｏｙｅａｕ　Ｒ　ｅｔ　ａｌ: Ｅｕｒ　Ｊ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．３５, 2000, ｐ．２５７-６６ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502397A (ja) * 2017-11-13 2021-01-28 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JP7257397B2 (ja) 2017-11-13 2023-04-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JP2022531794A (ja) * 2019-05-10 2022-07-11 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法
JP7587526B2 (ja) 2019-05-10 2024-11-20 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法

Also Published As

Publication number Publication date
RU2009127800A (ru) 2011-01-27
US20120015974A1 (en) 2012-01-19
CA2671607A1 (en) 2008-07-03
KR20090094461A (ko) 2009-09-07
NZ577150A (en) 2012-04-27
BRPI0719481A2 (pt) 2014-02-11
AU2007337104A1 (en) 2008-07-03
CN101605786A (zh) 2009-12-16
EP2125809A1 (en) 2009-12-02
IL198927A0 (en) 2010-02-17
RU2466131C2 (ru) 2012-11-10
US20100130539A1 (en) 2010-05-27
US8063218B2 (en) 2011-11-22
WO2008079735A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
JP5155184B2 (ja) Ｉａｐのインヒビター
RU2466131C2 (ru) Имидазопиридиновые ингибиторы iap
JP5368428B2 (ja) Ｉａｐのインヒビター
JP4850175B2 (ja) Ｉａｐのインヒビター
JP5007235B2 (ja) Ｉａｐのピロリジンインヒビター
JP5122275B2 (ja) Ｉａｐのアザビシクロ−オクタンインヒビター
US20110218211A1 (en) Azaindole inhibitors of iap
EP2240506B1 (en) Inhibitors of iap

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130220

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140401